ATRX News and Press, Adhera Therapeutics Inc From 10/14/21

The Covid story is starting to change. And you can hear the popping sound in the vaccine space. The needle is “therapeutics”. The therapeutic route was thought to be tricky for this virus on the near-term time horizon, which fueled a massive tsunami into the vaccine stocks as la...

The smaller cap biotech space offers two key advantages for investors right now: cyclical diversification and diversification away from the vaccine monolithic theme. To break that down a bit, the stock market has been volatile over the past month, with many growth plays getting smacked down a...

Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company fro...

The global diabetes market was estimated at $25.9 billion in 2020 and is expected to reach $28.5 billion in 2021 according to Grand View Research. The global market for diabetes care products including drugs and devices is even more impressive. This larger category is expected to exceed $111....

According to a recent report from MarketsAndMarkets.com, the global Parkinson’s disease treatment market is expected to reach $5.69 billion by 2022, growing from $4.24 billion in 2017, expanding at a CAGR of 6.1%.  The report notes that this market is being driven by rising geriat...

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-...

Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Andrew G. Reaume, Ph.D., MBA to the Company’s Board of Directors. Dr. R...

With the dominance of the giants in the Covid vaccine space, biotech stocks have outperformed the market this year by a wide margin. But almost all of that outperformance has been isolated in the large-cap factor zone in the space, leaving small-cap biotech players to badly lag the market. Th...

Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.) Laboratory and clinical research support MLR-1023 as the world’s first safe, effective beta cell proliferative agent Adhera ...

Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various p...